Abstract | PURPOSE: METHODS: RESULTS: At 1-month, her headaches and vision improved to 20/30 in both eyes with partial resolution of papilledema and complete restoration of visual fields. Nine months later, patient had 20/25 vision in right eye and 20/30 in left eye with complete resolution of papilledema and cerebral sinus thrombosis. CONCLUSIONS:
|
Authors | K V Chalam, S K Gupta, S Agarwal |
Journal | European journal of ophthalmology
(Eur J Ophthalmol)
2007 Sep-Oct
Vol. 17
Issue 5
Pg. 867-70
ISSN: 1120-6721 [Print] United States |
PMID | 17932872
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20
- Immunologic Factors
- Rituximab
|
Topics |
- Adult
- Antibodies, Monoclonal
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20
- Antiphospholipid Syndrome
(complications)
- Female
- Follow-Up Studies
- Humans
- Immunologic Factors
(administration & dosage, therapeutic use)
- Injections, Intravenous
- Magnetic Resonance Imaging
- Papilledema
(diagnosis, drug therapy, etiology)
- Phlebography
- Rituximab
- Sinus Thrombosis, Intracranial
(complications, diagnosis)
- Visual Acuity
|